{"id": "article-31484_0", "title": "Alpha-1 Antitrypsin Deficiency -- Continuing Education Activity", "content": "Alpha-1 antitrypsin (AAT) deficiency is a clinically under-recognized genetic disorder that causes the defective production of alpha-1 antitrypsin protein. AAT protein protects the body from the neutrophil elastase enzyme, which is released from white blood cells to fight infection. This activity discusses the evaluation and management of AAT and highlights the role of the interprofessional team in managing and treating the disease to improve patient care.", "contents": "Alpha-1 Antitrypsin Deficiency -- Continuing Education Activity. Alpha-1 antitrypsin (AAT) deficiency is a clinically under-recognized genetic disorder that causes the defective production of alpha-1 antitrypsin protein. AAT protein protects the body from the neutrophil elastase enzyme, which is released from white blood cells to fight infection. This activity discusses the evaluation and management of AAT and highlights the role of the interprofessional team in managing and treating the disease to improve patient care."}
{"id": "article-31484_1", "title": "Alpha-1 Antitrypsin Deficiency -- Continuing Education Activity", "content": "Objectives: Screen individuals with suspected alpha-1 antitrypsin deficiency using appropriate diagnostic modalities, such as serum alpha-1 antitrypsin levels, phenotyping, and genotyping, to confirm the diagnosis. Implement comprehensive management strategies for individuals with alpha-1 antitrypsin deficiency, including lifestyle modifications, smoking cessation interventions, vaccinations, and appropriate treatment options tailored to the specific manifestations of the disease. Select appropriate treatment options for alpha-1 antitrypsin deficiency, such as augmentation therapy, bronchodilators, glucocorticoids, or liver transplantation, based on the patient's clinical status, disease progression, and response to previous interventions. Coordinate appropriate follow-up and long-term care plans for individuals with alpha-1 antitrypsin deficiency, including regular monitoring, preventive interventions, and timely referrals to specialized centers or support groups. Access free multiple choice questions on this topic.", "contents": "Alpha-1 Antitrypsin Deficiency -- Continuing Education Activity. Objectives: Screen individuals with suspected alpha-1 antitrypsin deficiency using appropriate diagnostic modalities, such as serum alpha-1 antitrypsin levels, phenotyping, and genotyping, to confirm the diagnosis. Implement comprehensive management strategies for individuals with alpha-1 antitrypsin deficiency, including lifestyle modifications, smoking cessation interventions, vaccinations, and appropriate treatment options tailored to the specific manifestations of the disease. Select appropriate treatment options for alpha-1 antitrypsin deficiency, such as augmentation therapy, bronchodilators, glucocorticoids, or liver transplantation, based on the patient's clinical status, disease progression, and response to previous interventions. Coordinate appropriate follow-up and long-term care plans for individuals with alpha-1 antitrypsin deficiency, including regular monitoring, preventive interventions, and timely referrals to specialized centers or support groups. Access free multiple choice questions on this topic."}
{"id": "article-31484_2", "title": "Alpha-1 Antitrypsin Deficiency -- Introduction", "content": "Alpha-1 antitrypsin (AAT) deficiency is a genetically inherited disorder often unrecognized in clinical practice. It results in impaired production of alpha-1 antitrypsin protein, which plays a role in protecting the body from neutrophil elastase, an enzyme released by white blood cells during infection. Due to defective protein production, there is reduced activity of AAT in the blood and lungs. Additionally, abnormal AAT\u00a0levels can lead to the accumulation of AAT in the liver, leading to liver disease.", "contents": "Alpha-1 Antitrypsin Deficiency -- Introduction. Alpha-1 antitrypsin (AAT) deficiency is a genetically inherited disorder often unrecognized in clinical practice. It results in impaired production of alpha-1 antitrypsin protein, which plays a role in protecting the body from neutrophil elastase, an enzyme released by white blood cells during infection. Due to defective protein production, there is reduced activity of AAT in the blood and lungs. Additionally, abnormal AAT\u00a0levels can lead to the accumulation of AAT in the liver, leading to liver disease."}
{"id": "article-31484_3", "title": "Alpha-1 Antitrypsin Deficiency -- Introduction", "content": "Mutations in the SERPINA1 gene are responsible for\u00a0both deficiency and\u00a0the presence of\u00a0abnormal\u00a0AAT protein.\u00a0Inadequate levels of functional AAT result in the destruction of alveoli in the lungs by neutrophil elastase, leading to\u00a0lung disease. Abnormal AAT can also accumulate in the liver and cause damage to this organ.", "contents": "Alpha-1 Antitrypsin Deficiency -- Introduction. Mutations in the SERPINA1 gene are responsible for\u00a0both deficiency and\u00a0the presence of\u00a0abnormal\u00a0AAT protein.\u00a0Inadequate levels of functional AAT result in the destruction of alveoli in the lungs by neutrophil elastase, leading to\u00a0lung disease. Abnormal AAT can also accumulate in the liver and cause damage to this organ."}
{"id": "article-31484_4", "title": "Alpha-1 Antitrypsin Deficiency -- Introduction", "content": "Individuals with AAT deficiency usually\u00a0experience the initial manifestations of lung disease, such as emphysema and bronchiectasis, between the\u00a0age range of 20\u00a0to 50 years. Extensive research has consistently shown that cigarette smoking plays a significant role in lung function decline. [1] [2] [3] This\u00a0activity\u00a0will review the etiology, epidemiology,\u00a0clinical\u00a0manifestations, diagnosis, and\u00a0management\u00a0of\u00a0AAT deficiency.", "contents": "Alpha-1 Antitrypsin Deficiency -- Introduction. Individuals with AAT deficiency usually\u00a0experience the initial manifestations of lung disease, such as emphysema and bronchiectasis, between the\u00a0age range of 20\u00a0to 50 years. Extensive research has consistently shown that cigarette smoking plays a significant role in lung function decline. [1] [2] [3] This\u00a0activity\u00a0will review the etiology, epidemiology,\u00a0clinical\u00a0manifestations, diagnosis, and\u00a0management\u00a0of\u00a0AAT deficiency."}
{"id": "article-31484_5", "title": "Alpha-1 Antitrypsin Deficiency -- Etiology -- AAT Genetics", "content": "AAT deficiency is inherited\u00a0through autosomal co-dominant transmission, which\u00a0indicates that affected individuals have inherited an abnormal AAT gene from\u00a0both parents. The gene that encodes AAT is SERPINA1, located on the long arm of chromosome 14.", "contents": "Alpha-1 Antitrypsin Deficiency -- Etiology -- AAT Genetics. AAT deficiency is inherited\u00a0through autosomal co-dominant transmission, which\u00a0indicates that affected individuals have inherited an abnormal AAT gene from\u00a0both parents. The gene that encodes AAT is SERPINA1, located on the long arm of chromosome 14."}
{"id": "article-31484_6", "title": "Alpha-1 Antitrypsin Deficiency -- Etiology -- AAT Genetics", "content": "Over\u00a0150 alleles of AAT (SERPINA1) have been identified, and each\u00a0allele\u00a0is assigned a letter code based on the protein's electrophoretic mobility that it produces. The most common version (allele) of the SERPINA1 gene is referred to as the \"M\" allele, which is considered the normal allele. Most\u00a0individuals in the general population\u00a0possess\u00a0two copies of the M allele (MM) in each cell\u2014variations\u00a0of the SERPINA1 gene\u00a0result in\u00a0decreased levels of alpha-1 antitrypsin. For example, the S allele\u00a0leads to moderately low levels of this protein,\u00a0while the Z allele\u00a0results in significantly reduced\u00a0AAT. Individuals\u00a0who carry\u00a02 copies of the Z allele (ZZ) in each cell will likely have AAT deficiency. Those with the SZ combination are more likely to develop lung diseases, such as emphysema, particularly if they smoke.", "contents": "Alpha-1 Antitrypsin Deficiency -- Etiology -- AAT Genetics. Over\u00a0150 alleles of AAT (SERPINA1) have been identified, and each\u00a0allele\u00a0is assigned a letter code based on the protein's electrophoretic mobility that it produces. The most common version (allele) of the SERPINA1 gene is referred to as the \"M\" allele, which is considered the normal allele. Most\u00a0individuals in the general population\u00a0possess\u00a0two copies of the M allele (MM) in each cell\u2014variations\u00a0of the SERPINA1 gene\u00a0result in\u00a0decreased levels of alpha-1 antitrypsin. For example, the S allele\u00a0leads to moderately low levels of this protein,\u00a0while the Z allele\u00a0results in significantly reduced\u00a0AAT. Individuals\u00a0who carry\u00a02 copies of the Z allele (ZZ) in each cell will likely have AAT deficiency. Those with the SZ combination are more likely to develop lung diseases, such as emphysema, particularly if they smoke."}
{"id": "article-31484_7", "title": "Alpha-1 Antitrypsin Deficiency -- Etiology -- AAT Genetics", "content": "Worldwide, it is estimated that 161 million people\u00a0carry\u00a01 copy of the S or Z allele and\u00a01 copy of the M allele in each cell (MS or MZ). Individuals with an MS (or SS) combination\u00a0typically produce\u00a0sufficient amounts of\u00a0alpha-1 antitrypsin to protect their lungs. However, people carrying MZ alleles have a slightly increased risk of experiencing impaired lung or liver function.", "contents": "Alpha-1 Antitrypsin Deficiency -- Etiology -- AAT Genetics. Worldwide, it is estimated that 161 million people\u00a0carry\u00a01 copy of the S or Z allele and\u00a01 copy of the M allele in each cell (MS or MZ). Individuals with an MS (or SS) combination\u00a0typically produce\u00a0sufficient amounts of\u00a0alpha-1 antitrypsin to protect their lungs. However, people carrying MZ alleles have a slightly increased risk of experiencing impaired lung or liver function."}
{"id": "article-31484_8", "title": "Alpha-1 Antitrypsin Deficiency -- Etiology -- AAT Phenotypes", "content": "AAT phenotypes are based on the electrophoretic mobility of the proteins produced by the various abnormal AAT alleles. Genotyping is performed by identifying specific alleles in DNA. Based on this, variants of AAT can be categorized into four basic groups: [4]", "contents": "Alpha-1 Antitrypsin Deficiency -- Etiology -- AAT Phenotypes. AAT phenotypes are based on the electrophoretic mobility of the proteins produced by the various abnormal AAT alleles. Genotyping is performed by identifying specific alleles in DNA. Based on this, variants of AAT can be categorized into four basic groups: [4]"}
{"id": "article-31484_9", "title": "Alpha-1 Antitrypsin Deficiency -- Etiology -- AAT Phenotypes", "content": "Normal is associated with normal levels of AAT and\u00a0its proper\u00a0functioning. The\u00a0group of normal alleles is\u00a0referred to as M, and the\u00a0typical genotype with normal AAT levels is MM.", "contents": "Alpha-1 Antitrypsin Deficiency -- Etiology -- AAT Phenotypes. Normal is associated with normal levels of AAT and\u00a0its proper\u00a0functioning. The\u00a0group of normal alleles is\u00a0referred to as M, and the\u00a0typical genotype with normal AAT levels is MM."}
{"id": "article-31484_10", "title": "Alpha-1 Antitrypsin Deficiency -- Etiology -- AAT Phenotypes", "content": "Deficient is associated\u00a0with a deficiency in\u00a0plasma AAT levels below\u00a035% of the average normal level.\u00a0Homozygotes with AAT deficiency typically have 5 to 6 \u03bcmol/L plasma levels. The most common deficient allele associated with emphysema is the Z allele, which is\u00a0present in approximately 2% to 3% of the\u00a0Caucasian population in the United States.", "contents": "Alpha-1 Antitrypsin Deficiency -- Etiology -- AAT Phenotypes. Deficient is associated\u00a0with a deficiency in\u00a0plasma AAT levels below\u00a035% of the average normal level.\u00a0Homozygotes with AAT deficiency typically have 5 to 6 \u03bcmol/L plasma levels. The most common deficient allele associated with emphysema is the Z allele, which is\u00a0present in approximately 2% to 3% of the\u00a0Caucasian population in the United States."}
{"id": "article-31484_11", "title": "Alpha-1 Antitrypsin Deficiency -- Etiology -- AAT Phenotypes", "content": "Null alleles\u00a0result in the absence of detectable AAT protein in the plasma. Therefore, individuals\u00a0with the null genotype are\u00a0less common and are at higher\u00a0risk for the most severe form of lung disease, while liver disease is not typically associated with null alleles.", "contents": "Alpha-1 Antitrypsin Deficiency -- Etiology -- AAT Phenotypes. Null alleles\u00a0result in the absence of detectable AAT protein in the plasma. Therefore, individuals\u00a0with the null genotype are\u00a0less common and are at higher\u00a0risk for the most severe form of lung disease, while liver disease is not typically associated with null alleles."}
{"id": "article-31484_12", "title": "Alpha-1 Antitrypsin Deficiency -- Etiology -- AAT Phenotypes", "content": "Dysfunctional alleles\u00a0are characterized by producing a normal quantity of AAT protein, but the protein\u00a0fails to\u00a0function properly. This dysfunction can be attributed to either a conversion defect from an elastase inhibitor to a thrombin inhibitor\u00a0or the presence of the PI*F variant. [5] [6]", "contents": "Alpha-1 Antitrypsin Deficiency -- Etiology -- AAT Phenotypes. Dysfunctional alleles\u00a0are characterized by producing a normal quantity of AAT protein, but the protein\u00a0fails to\u00a0function properly. This dysfunction can be attributed to either a conversion defect from an elastase inhibitor to a thrombin inhibitor\u00a0or the presence of the PI*F variant. [5] [6]"}
{"id": "article-31484_13", "title": "Alpha-1 Antitrypsin Deficiency -- Epidemiology", "content": "AAT  deficiency is a condition that is present worldwide, but its prevalence varies\u00a0among different populations. This\u00a0condition\u00a0affects\u00a0approximately 1 in 2,000 to 6,000 individuals and predisposes them to liver disease and early-onset emphysema.\u00a0AAT deficiency is more prevalent among\u00a0individuals of European ancestry and\u00a0relatively less common\u00a0among individuals of Asian descent and other ancestries. [6] [7]", "contents": "Alpha-1 Antitrypsin Deficiency -- Epidemiology. AAT  deficiency is a condition that is present worldwide, but its prevalence varies\u00a0among different populations. This\u00a0condition\u00a0affects\u00a0approximately 1 in 2,000 to 6,000 individuals and predisposes them to liver disease and early-onset emphysema.\u00a0AAT deficiency is more prevalent among\u00a0individuals of European ancestry and\u00a0relatively less common\u00a0among individuals of Asian descent and other ancestries. [6] [7]"}
{"id": "article-31484_14", "title": "Alpha-1 Antitrypsin Deficiency -- Epidemiology", "content": "While\u00a0AAT deficiency is classified as a rare condition,\u00a0it is believed that approximately\u00a080,000 to 100,000 individuals in the\u00a0United States have a severe deficiency of AAT, suggesting that the disease is likely under-recognized. Globally, it is estimated that more than\u00a03 million people have allele combinations associated with severe\u00a0AAT deficiency. [8] [9]", "contents": "Alpha-1 Antitrypsin Deficiency -- Epidemiology. While\u00a0AAT deficiency is classified as a rare condition,\u00a0it is believed that approximately\u00a080,000 to 100,000 individuals in the\u00a0United States have a severe deficiency of AAT, suggesting that the disease is likely under-recognized. Globally, it is estimated that more than\u00a03 million people have allele combinations associated with severe\u00a0AAT deficiency. [8] [9]"}
{"id": "article-31484_15", "title": "Alpha-1 Antitrypsin Deficiency -- Pathophysiology", "content": "AAT is a protease inhibitor produced in the liver to protect the lung against damage\u00a0caused by neutrophil elastase.\u00a0When\u00a0AAT misfolds, it forms abnormal polymers that accumulate as hepatocyte inclusions. These inclusions\u00a0can be detected\u00a0as positive on periodic acid\u2013Schiff staining with diastase digestion (PAS-D). The presence of misfolded AAT protein\u00a0can induce hepatotoxic stress, contributing to the development of liver disease.\u00a0Likewise, AAT deficiency leads to excess neutrophil elastase, which\u00a0promotes mucin production and\u00a0enhances the expression of other proteases and inflammatory cytokines. [10]", "contents": "Alpha-1 Antitrypsin Deficiency -- Pathophysiology. AAT is a protease inhibitor produced in the liver to protect the lung against damage\u00a0caused by neutrophil elastase.\u00a0When\u00a0AAT misfolds, it forms abnormal polymers that accumulate as hepatocyte inclusions. These inclusions\u00a0can be detected\u00a0as positive on periodic acid\u2013Schiff staining with diastase digestion (PAS-D). The presence of misfolded AAT protein\u00a0can induce hepatotoxic stress, contributing to the development of liver disease.\u00a0Likewise, AAT deficiency leads to excess neutrophil elastase, which\u00a0promotes mucin production and\u00a0enhances the expression of other proteases and inflammatory cytokines. [10]"}
{"id": "article-31484_16", "title": "Alpha-1 Antitrypsin Deficiency -- Pathophysiology", "content": "Environmental factors, such as exposure to tobacco smoke, chemicals, and dust, likely impact the severity of alpha-1 antitrypsin deficiency. The underlying causes of AAT deficiency vary depending on the affected organ. In the case of AAT emphysema, the primary etiology\u00a0is an imbalance between neutrophil elastase in the lungs and the elastase inhibitor AAT. [10] This imbalance becomes more pronounced when\u00a0exposed\u00a0to factors such as cigarette\u00a0smoke and infections, increasing the elastase burden in the lung,\u00a0and leading to accelerated lung tissue degradation. [11]", "contents": "Alpha-1 Antitrypsin Deficiency -- Pathophysiology. Environmental factors, such as exposure to tobacco smoke, chemicals, and dust, likely impact the severity of alpha-1 antitrypsin deficiency. The underlying causes of AAT deficiency vary depending on the affected organ. In the case of AAT emphysema, the primary etiology\u00a0is an imbalance between neutrophil elastase in the lungs and the elastase inhibitor AAT. [10] This imbalance becomes more pronounced when\u00a0exposed\u00a0to factors such as cigarette\u00a0smoke and infections, increasing the elastase burden in the lung,\u00a0and leading to accelerated lung tissue degradation. [11]"}
{"id": "article-31484_17", "title": "Alpha-1 Antitrypsin Deficiency -- Pathophysiology", "content": "Severe deficiency of AAT\u00a0is a\u00a0significant risk factor for early-onset emphysema,\u00a0although not\u00a0all individuals with\u00a0severe\u00a0deficiency\u00a0will develop emphysema. [11] Risk factors contributing to emphysema development\u00a0include cigarette smoking, dusty occupational exposure, parental history of chronic obstructive pulmonary disease (COPD), and a personal history of asthma, chronic bronchitis, or pneumonia.", "contents": "Alpha-1 Antitrypsin Deficiency -- Pathophysiology. Severe deficiency of AAT\u00a0is a\u00a0significant risk factor for early-onset emphysema,\u00a0although not\u00a0all individuals with\u00a0severe\u00a0deficiency\u00a0will develop emphysema. [11] Risk factors contributing to emphysema development\u00a0include cigarette smoking, dusty occupational exposure, parental history of chronic obstructive pulmonary disease (COPD), and a personal history of asthma, chronic bronchitis, or pneumonia."}
{"id": "article-31484_18", "title": "Alpha-1 Antitrypsin Deficiency -- Pathophysiology", "content": "AAT-related liver cirrhosis occurs due to the accumulation of\u00a0abnormal AAT protein within the hepatocytes. [12] The liver disease develops due to the\u00a0accumulation of unsecreted variant AAT protein within the hepatocytes. Only genotypes associated with the pathologic polymerization of AAT within the endoplasmic reticulum of hepatocytes produce the disease. Most patients with AAT-related liver disease are homozygous for the Z allele (PI*ZZ genotype).\u00a0Liver disease is not observed in null homozygotes with severe AAT deficiency but\u00a0lack intra-hepatocytic accumulation.", "contents": "Alpha-1 Antitrypsin Deficiency -- Pathophysiology. AAT-related liver cirrhosis occurs due to the accumulation of\u00a0abnormal AAT protein within the hepatocytes. [12] The liver disease develops due to the\u00a0accumulation of unsecreted variant AAT protein within the hepatocytes. Only genotypes associated with the pathologic polymerization of AAT within the endoplasmic reticulum of hepatocytes produce the disease. Most patients with AAT-related liver disease are homozygous for the Z allele (PI*ZZ genotype).\u00a0Liver disease is not observed in null homozygotes with severe AAT deficiency but\u00a0lack intra-hepatocytic accumulation."}
{"id": "article-31484_19", "title": "Alpha-1 Antitrypsin Deficiency -- History and Physical", "content": "AAT deficiency primarily affects three different organs, leading to distinct clinical manifestations: the lungs, the liver, and, in rare cases, the skin.", "contents": "Alpha-1 Antitrypsin Deficiency -- History and Physical. AAT deficiency primarily affects three different organs, leading to distinct clinical manifestations: the lungs, the liver, and, in rare cases, the skin."}
{"id": "article-31484_20", "title": "Alpha-1 Antitrypsin Deficiency -- History and Physical", "content": "The clinical presentation of lung diseases associated with AAT deficiency, such as emphysema, shares many similarities with typical COPD, including a significant portion of affected individuals having a smoking history. However, two\u00a0distinct characteristics of\u00a0AAT-related emphysema are the early onset\u00a0of symptoms at a young age and a basilar-predominant pattern of emphysema. [13] Individuals with AAT-related emphysema experience symptoms at a younger age and typically have a lower forced expiratory volume in 1 second (FEV 1 ) values.\u00a0According to\u00a0data from the National Institute of Health-sponsored registry for patients with AAT,\u00a0the mean FEV 1 was 43% \u00b1 30% of predicted, and the mean age was 46 \u00b1 11 years. [14]", "contents": "Alpha-1 Antitrypsin Deficiency -- History and Physical. The clinical presentation of lung diseases associated with AAT deficiency, such as emphysema, shares many similarities with typical COPD, including a significant portion of affected individuals having a smoking history. However, two\u00a0distinct characteristics of\u00a0AAT-related emphysema are the early onset\u00a0of symptoms at a young age and a basilar-predominant pattern of emphysema. [13] Individuals with AAT-related emphysema experience symptoms at a younger age and typically have a lower forced expiratory volume in 1 second (FEV 1 ) values.\u00a0According to\u00a0data from the National Institute of Health-sponsored registry for patients with AAT,\u00a0the mean FEV 1 was 43% \u00b1 30% of predicted, and the mean age was 46 \u00b1 11 years. [14]"}
{"id": "article-31484_21", "title": "Alpha-1 Antitrypsin Deficiency -- History and Physical", "content": "Dyspnea is the most common presenting symptom among individuals with AAT deficiency.\u00a0Many patients\u00a0also experience a chronic cough, sputum production, and wheezing,\u00a0both chronically or with upper respiratory tract infections. Spontaneous secondary pneumothorax may be the initial presenting\u00a0symptom of AAT deficiency or a complication of the\u00a0underlying disease. Severe AAT deficiency has also been linked to the development of bronchiectasis. Clinical presentation of extrapulmonary disease\u00a0in patients with at-risk alleles (eg, Z, S[iiyama], and M[malton]) may develop adult-onset chronic hepatitis, cirrhosis, or hepatocellular carcinoma.", "contents": "Alpha-1 Antitrypsin Deficiency -- History and Physical. Dyspnea is the most common presenting symptom among individuals with AAT deficiency.\u00a0Many patients\u00a0also experience a chronic cough, sputum production, and wheezing,\u00a0both chronically or with upper respiratory tract infections. Spontaneous secondary pneumothorax may be the initial presenting\u00a0symptom of AAT deficiency or a complication of the\u00a0underlying disease. Severe AAT deficiency has also been linked to the development of bronchiectasis. Clinical presentation of extrapulmonary disease\u00a0in patients with at-risk alleles (eg, Z, S[iiyama], and M[malton]) may develop adult-onset chronic hepatitis, cirrhosis, or hepatocellular carcinoma."}
{"id": "article-31484_22", "title": "Alpha-1 Antitrypsin Deficiency -- History and Physical", "content": "AAT deficiency can also manifest in various extrapulmonary ways.\u00a0These include necrotizing panniculitis, erythematous nodules, or plaques on the thigh or buttocks, which are the primary dermatologic manifestation of the condition. Other extrapulmonary manifestations are systemic vasculitis (such as Wegner granulomatosis), intracranial and peripheral aneurysms, psoriasis, urticaria, angioedema, potential association with inflammatory bowel disease, fibromuscular dysplasia, peripheral neuropathy, and glomerulonephritis. [15] [16] [17]", "contents": "Alpha-1 Antitrypsin Deficiency -- History and Physical. AAT deficiency can also manifest in various extrapulmonary ways.\u00a0These include necrotizing panniculitis, erythematous nodules, or plaques on the thigh or buttocks, which are the primary dermatologic manifestation of the condition. Other extrapulmonary manifestations are systemic vasculitis (such as Wegner granulomatosis), intracranial and peripheral aneurysms, psoriasis, urticaria, angioedema, potential association with inflammatory bowel disease, fibromuscular dysplasia, peripheral neuropathy, and glomerulonephritis. [15] [16] [17]"}
{"id": "article-31484_23", "title": "Alpha-1 Antitrypsin Deficiency -- Evaluation", "content": "Most individuals affected\u00a0by AAT deficiency remain undiagnosed\u00a0due to limited\u00a0access to\u00a0adequate\u00a0healthcare and treatment. [13] Screening for AAT deficiency is essential and\u00a0should be conducted\u00a0using\u00a0various\u00a0diagnostic methods. It is crucial to maintain\u00a0a low threshold for clinical suspicion. In addition to testing first-degree relatives of\u00a0individuals with AAT deficiency, it is important to screen patients with one or more of the following disorders: [10] [18] COPD: Emphysema type\u00a0in a young individual (\u226445 years), nonsmoker or minimal smoker, or\u00a0display a\u00a0 predominant basilar radiological pattern. Unexplained liver disease or family history of liver disease Poorly responsive asthma c-ANCA vasculitis (in >90% of cases, the antibody is specific for proteinase 3) Panniculitis Bronchiectasis not related to cystic fibrosis Initial evaluation for clinically suspected ATT deficiency includes:", "contents": "Alpha-1 Antitrypsin Deficiency -- Evaluation. Most individuals affected\u00a0by AAT deficiency remain undiagnosed\u00a0due to limited\u00a0access to\u00a0adequate\u00a0healthcare and treatment. [13] Screening for AAT deficiency is essential and\u00a0should be conducted\u00a0using\u00a0various\u00a0diagnostic methods. It is crucial to maintain\u00a0a low threshold for clinical suspicion. In addition to testing first-degree relatives of\u00a0individuals with AAT deficiency, it is important to screen patients with one or more of the following disorders: [10] [18] COPD: Emphysema type\u00a0in a young individual (\u226445 years), nonsmoker or minimal smoker, or\u00a0display a\u00a0 predominant basilar radiological pattern. Unexplained liver disease or family history of liver disease Poorly responsive asthma c-ANCA vasculitis (in >90% of cases, the antibody is specific for proteinase 3) Panniculitis Bronchiectasis not related to cystic fibrosis Initial evaluation for clinically suspected ATT deficiency includes:"}
{"id": "article-31484_24", "title": "Alpha-1 Antitrypsin Deficiency -- Evaluation", "content": "Medical history & physical examination", "contents": "Alpha-1 Antitrypsin Deficiency -- Evaluation. Medical history & physical examination"}
{"id": "article-31484_25", "title": "Alpha-1 Antitrypsin Deficiency -- Evaluation", "content": "Liver-function tests", "contents": "Alpha-1 Antitrypsin Deficiency -- Evaluation. Liver-function tests"}
{"id": "article-31484_26", "title": "Alpha-1 Antitrypsin Deficiency -- Evaluation", "content": "Complete pulmonary function tests (PFT): PFT\u00a0is used to\u00a0evaluate the presence and\u00a0extent of lung disease. This includes spirometry, typically obtained before and after bronchodilator administration, and assessments of lung volumes and diffusing capacity for carbon monoxide (DLCO). A six-minute walk test should be conducted if DLCO\u00a0falls below the normal range or if the patient reports exertional dyspnea. All adults with persistent airflow obstruction on spirometry, particularly those residing in regions with a high prevalence of AAT deficiency, should undergo testing for AAT deficiency.", "contents": "Alpha-1 Antitrypsin Deficiency -- Evaluation. Complete pulmonary function tests (PFT): PFT\u00a0is used to\u00a0evaluate the presence and\u00a0extent of lung disease. This includes spirometry, typically obtained before and after bronchodilator administration, and assessments of lung volumes and diffusing capacity for carbon monoxide (DLCO). A six-minute walk test should be conducted if DLCO\u00a0falls below the normal range or if the patient reports exertional dyspnea. All adults with persistent airflow obstruction on spirometry, particularly those residing in regions with a high prevalence of AAT deficiency, should undergo testing for AAT deficiency."}
{"id": "article-31484_27", "title": "Alpha-1 Antitrypsin Deficiency -- Evaluation", "content": "Chest radiography: A chest X-ray is used to determine the pattern and extent of emphysema and to exclude other causes of dyspnea. The \u201cclassic\u201d pattern of emphysema\u00a0observed in\u00a0AAT deficiency typically manifests as basilar-predominant emphysematous bullae.\u00a0However, a range of patterns from basilar-predominant to apical-predominant emphysema may be seen. Some clinicians perform chest computed tomography (CT) scans for an initial assessment. [19] [20]", "contents": "Alpha-1 Antitrypsin Deficiency -- Evaluation. Chest radiography: A chest X-ray is used to determine the pattern and extent of emphysema and to exclude other causes of dyspnea. The \u201cclassic\u201d pattern of emphysema\u00a0observed in\u00a0AAT deficiency typically manifests as basilar-predominant emphysematous bullae.\u00a0However, a range of patterns from basilar-predominant to apical-predominant emphysema may be seen. Some clinicians perform chest computed tomography (CT) scans for an initial assessment. [19] [20]"}
{"id": "article-31484_28", "title": "Alpha-1 Antitrypsin Deficiency -- Evaluation", "content": "Confirm AAT deficiency: Severe AAT deficiency is diagnosed by confirming a serum level below 11 \u03bcmols/L (approximately 57 mg/dL by nephelometry), along with the presence of a severely deficient\u00a0genotype\u00a0identified through\u00a0testing for the most common defective alleles (ie, S, Z, I, F).", "contents": "Alpha-1 Antitrypsin Deficiency -- Evaluation. Confirm AAT deficiency: Severe AAT deficiency is diagnosed by confirming a serum level below 11 \u03bcmols/L (approximately 57 mg/dL by nephelometry), along with the presence of a severely deficient\u00a0genotype\u00a0identified through\u00a0testing for the most common defective alleles (ie, S, Z, I, F)."}
{"id": "article-31484_29", "title": "Alpha-1 Antitrypsin Deficiency -- Evaluation", "content": "If\u00a0the AAT serum level is greater than 20 \u03bcmol/L, the patient is unlikely to have a clinically significant AAT deficiency. However, genotyping becomes necessary if\u00a0there is a need to assess\u00a0the presence of\u00a0particular mutations or identify heterozygotes and mutations with incomplete penetrance.", "contents": "Alpha-1 Antitrypsin Deficiency -- Evaluation. If\u00a0the AAT serum level is greater than 20 \u03bcmol/L, the patient is unlikely to have a clinically significant AAT deficiency. However, genotyping becomes necessary if\u00a0there is a need to assess\u00a0the presence of\u00a0particular mutations or identify heterozygotes and mutations with incomplete penetrance."}
{"id": "article-31484_30", "title": "Alpha-1 Antitrypsin Deficiency -- Evaluation", "content": "The normal plasma concentration of AAT ranges from 80\u00a0mg/dL\u00a0to 220 mg/dL (20 to 48 \u03bcmol/L using nephelometry or 150\u00a0mg/dL\u00a0to 350 mg/dL by radial immunodiffusion). However, given the variability in reference ranges, patients with a serum AAT level below 100 mg/dL (18.4 \u03bcmols/L) should be evaluated further with isoelectric focusing or genotyping. Isoelectric focusing is the gold standard blood test for identifying AAT variants and is\u00a0commonly used as a phenotype test.", "contents": "Alpha-1 Antitrypsin Deficiency -- Evaluation. The normal plasma concentration of AAT ranges from 80\u00a0mg/dL\u00a0to 220 mg/dL (20 to 48 \u03bcmol/L using nephelometry or 150\u00a0mg/dL\u00a0to 350 mg/dL by radial immunodiffusion). However, given the variability in reference ranges, patients with a serum AAT level below 100 mg/dL (18.4 \u03bcmols/L) should be evaluated further with isoelectric focusing or genotyping. Isoelectric focusing is the gold standard blood test for identifying AAT variants and is\u00a0commonly used as a phenotype test."}
{"id": "article-31484_31", "title": "Alpha-1 Antitrypsin Deficiency -- Evaluation", "content": "Genotyping of the protease inhibitor (Pi) locus is performed on a blood sample using polymerase chain reaction (PCR) technology or restriction fragment length polymorphisms. These tests detect the most commonly known variants (F, I, S, Z). In cases where these tests fail to determine the genetic variant, gene sequencing of exonic DNA can be employed as an alternative method.", "contents": "Alpha-1 Antitrypsin Deficiency -- Evaluation. Genotyping of the protease inhibitor (Pi) locus is performed on a blood sample using polymerase chain reaction (PCR) technology or restriction fragment length polymorphisms. These tests detect the most commonly known variants (F, I, S, Z). In cases where these tests fail to determine the genetic variant, gene sequencing of exonic DNA can be employed as an alternative method."}
{"id": "article-31484_32", "title": "Alpha-1 Antitrypsin Deficiency -- Evaluation", "content": "When\u00a0monitoring asymptomatic patients, who do not exhibit respiratory symptoms and have normal baseline spirometry (ie, FEV1 80% or greater than predicted), spirometry should be repeated\u00a0if symptoms change at 6 to 12-month intervals. An unexplained decrease in the post-bronchodilator FEV1 to less than 80% predicted is an indication to consider\u00a0initiating\u00a0augmentation therapy.", "contents": "Alpha-1 Antitrypsin Deficiency -- Evaluation. When\u00a0monitoring asymptomatic patients, who do not exhibit respiratory symptoms and have normal baseline spirometry (ie, FEV1 80% or greater than predicted), spirometry should be repeated\u00a0if symptoms change at 6 to 12-month intervals. An unexplained decrease in the post-bronchodilator FEV1 to less than 80% predicted is an indication to consider\u00a0initiating\u00a0augmentation therapy."}
{"id": "article-31484_33", "title": "Alpha-1 Antitrypsin Deficiency -- Evaluation", "content": "There is a lack of specific guidelines for monitoring liver disease in patients homozygous for PiZ, PiS[iiyama], or PiM[malton]. It is\u00a0recommended to assess serum aminotransferases, alkaline phosphatase, and bilirubin annually.\u00a0Additionally, some clinicians also obtain a complete blood count (CBC)\u00a0to check for thrombocytopenia and\u00a0perform abdominal ultrasounds every 6 to 12 months to evaluate for the presence of cirrhosis.", "contents": "Alpha-1 Antitrypsin Deficiency -- Evaluation. There is a lack of specific guidelines for monitoring liver disease in patients homozygous for PiZ, PiS[iiyama], or PiM[malton]. It is\u00a0recommended to assess serum aminotransferases, alkaline phosphatase, and bilirubin annually.\u00a0Additionally, some clinicians also obtain a complete blood count (CBC)\u00a0to check for thrombocytopenia and\u00a0perform abdominal ultrasounds every 6 to 12 months to evaluate for the presence of cirrhosis."}
{"id": "article-31484_34", "title": "Alpha-1 Antitrypsin Deficiency -- Evaluation", "content": "The phenotype presentation of AAT deficiency\u00a0can vary, even in individuals\u00a0with confirmed low levels of AAT. The variation is strongly linked\u00a0to factors such as exposure to cigarette smoking and occupational exposures,\u00a0including exposure to kerosene or dust. [21]", "contents": "Alpha-1 Antitrypsin Deficiency -- Evaluation. The phenotype presentation of AAT deficiency\u00a0can vary, even in individuals\u00a0with confirmed low levels of AAT. The variation is strongly linked\u00a0to factors such as exposure to cigarette smoking and occupational exposures,\u00a0including exposure to kerosene or dust. [21]"}
{"id": "article-31484_35", "title": "Alpha-1 Antitrypsin Deficiency -- Treatment / Management", "content": "It is crucial for all\u00a0patients suspected or diagnosed with AAT deficiency\u00a0to quit smoking. Individuals with severe AAT deficiency, such as those with\u00a0PI ZZ or null genotypes, should\u00a0undergo regular\u00a0monitoring with pulmonary function testing and\u00a06-minute walk testing, clinical assessments, and evaluations of the quality of life. These monitoring activities should be conducted periodically, typically every 6 to 12 months, to assess disease progression and the effectiveness of interventions. [13]", "contents": "Alpha-1 Antitrypsin Deficiency -- Treatment / Management. It is crucial for all\u00a0patients suspected or diagnosed with AAT deficiency\u00a0to quit smoking. Individuals with severe AAT deficiency, such as those with\u00a0PI ZZ or null genotypes, should\u00a0undergo regular\u00a0monitoring with pulmonary function testing and\u00a06-minute walk testing, clinical assessments, and evaluations of the quality of life. These monitoring activities should be conducted periodically, typically every 6 to 12 months, to assess disease progression and the effectiveness of interventions. [13]"}
{"id": "article-31484_36", "title": "Alpha-1 Antitrypsin Deficiency -- Treatment / Management", "content": "Supportive treatments include inhaled bronchodilators and inhaled or oral glucocorticoids, as recommended by the guidelines for managing COPD. [22] Additional considerations should include\u00a0evaluating the need for home oxygen supplementation if resting oxygen saturation falls below 88%. Preventive vaccination against respiratory viral infections, such as influenza, and pneumococcal pneumonia, should be prioritized. [23] Pulmonary rehabilitation and nutritional support are also important components of comprehensive care for these patients. [24]", "contents": "Alpha-1 Antitrypsin Deficiency -- Treatment / Management. Supportive treatments include inhaled bronchodilators and inhaled or oral glucocorticoids, as recommended by the guidelines for managing COPD. [22] Additional considerations should include\u00a0evaluating the need for home oxygen supplementation if resting oxygen saturation falls below 88%. Preventive vaccination against respiratory viral infections, such as influenza, and pneumococcal pneumonia, should be prioritized. [23] Pulmonary rehabilitation and nutritional support are also important components of comprehensive care for these patients. [24]"}
{"id": "article-31484_37", "title": "Alpha-1 Antitrypsin Deficiency -- Treatment / Management", "content": "Intravenous augmentation, which\u00a0involves the infusion of pooled plasma-purified human alpha-1 antitrypsin (an alpha-1 proteinase inhibitor), is\u00a0the only licensed disease-specific therapy for AAT deficiency associated with lung disease.\u00a0It was licensed\u00a0by the Food and Drug Administration in 1987 and has been the most direct and efficient means of elevating AAT levels in the plasma and the lung interstitium. [13] [25] [26] [27] Although augmentation therapy has been shown to decrease the loss of lung density in individuals with AAT deficiency, there is no evidence that it impacts lung function (FEV1), quality of life, or rates of COPD exacerbation. [28]", "contents": "Alpha-1 Antitrypsin Deficiency -- Treatment / Management. Intravenous augmentation, which\u00a0involves the infusion of pooled plasma-purified human alpha-1 antitrypsin (an alpha-1 proteinase inhibitor), is\u00a0the only licensed disease-specific therapy for AAT deficiency associated with lung disease.\u00a0It was licensed\u00a0by the Food and Drug Administration in 1987 and has been the most direct and efficient means of elevating AAT levels in the plasma and the lung interstitium. [13] [25] [26] [27] Although augmentation therapy has been shown to decrease the loss of lung density in individuals with AAT deficiency, there is no evidence that it impacts lung function (FEV1), quality of life, or rates of COPD exacerbation. [28]"}
{"id": "article-31484_38", "title": "Alpha-1 Antitrypsin Deficiency -- Treatment / Management", "content": "The American Thoracic Society suggests weekly augmentation therapy with human pooled AAT for individuals with plasma levels of AAT less than 11 \u03bcmols/L and established airflow obstruction, defined as an FEV1 less than 80% predicted. On the other hand, the Canadian Thoracic Society suggests keeping AAT augmentation therapy for AAT-deficient patients (AAT level less than 11 \u03bcmols/L) with an FEV1 of 25% to 80% predicted who have quit smoking and are on optimal medical therapy. The thoracic society of Australia and New Zealand recommend augmentation therapy to be considered in non-smoking patients with AAT deficiency (as a conditional recommendation and low-quality evidence). [29] The selection criteria for augmentation therapy include the following: High-risk phenotype Plasma AAT level below 11 \u03bcmols/L Airflow obstruction by spirometry (eg, FEV1\u00a0<80% of predicted) Likely compliance with the protocol Age\u00a0\u226518 years Nonsmoker or ex-smoker", "contents": "Alpha-1 Antitrypsin Deficiency -- Treatment / Management. The American Thoracic Society suggests weekly augmentation therapy with human pooled AAT for individuals with plasma levels of AAT less than 11 \u03bcmols/L and established airflow obstruction, defined as an FEV1 less than 80% predicted. On the other hand, the Canadian Thoracic Society suggests keeping AAT augmentation therapy for AAT-deficient patients (AAT level less than 11 \u03bcmols/L) with an FEV1 of 25% to 80% predicted who have quit smoking and are on optimal medical therapy. The thoracic society of Australia and New Zealand recommend augmentation therapy to be considered in non-smoking patients with AAT deficiency (as a conditional recommendation and low-quality evidence). [29] The selection criteria for augmentation therapy include the following: High-risk phenotype Plasma AAT level below 11 \u03bcmols/L Airflow obstruction by spirometry (eg, FEV1\u00a0<80% of predicted) Likely compliance with the protocol Age\u00a0\u226518 years Nonsmoker or ex-smoker"}
{"id": "article-31484_39", "title": "Alpha-1 Antitrypsin Deficiency -- Treatment / Management", "content": "Augmentation therapy is not recommended for patients with heterozygous phenotypes, whose plasma AAT level exceeds 11 \u03bcmols/L, or current smokers. Side effects associated with\u00a0intravenous\u00a0AAT infusion are uncommon, and no long-term reactions have been noted. However, some side effects can occur, including: Low-grade fever and mild flu-like symptoms are usually self-limited. Anaphylaxis with IgE antibody formation to AAT has been reported, which is extremely\u00a0rare. A syndrome of transient fever, chest and low back pain, and thrombocytopenia has been reported.\u00a0This is due to a high molecular weight contaminant in the stabilizer added to the AAT product. Pooled human plasma alpha 1-antiprotease contains small amounts of IgA, so IgA-deficient individuals with anti-IgA antibodies are at risk of anaphylaxis with current infusions. Therefore, checking for IgA deficiency ((level <7 mg/dL) or anti-IgA antibodies is recommended before initiating intravenous AAT therapy.", "contents": "Alpha-1 Antitrypsin Deficiency -- Treatment / Management. Augmentation therapy is not recommended for patients with heterozygous phenotypes, whose plasma AAT level exceeds 11 \u03bcmols/L, or current smokers. Side effects associated with\u00a0intravenous\u00a0AAT infusion are uncommon, and no long-term reactions have been noted. However, some side effects can occur, including: Low-grade fever and mild flu-like symptoms are usually self-limited. Anaphylaxis with IgE antibody formation to AAT has been reported, which is extremely\u00a0rare. A syndrome of transient fever, chest and low back pain, and thrombocytopenia has been reported.\u00a0This is due to a high molecular weight contaminant in the stabilizer added to the AAT product. Pooled human plasma alpha 1-antiprotease contains small amounts of IgA, so IgA-deficient individuals with anti-IgA antibodies are at risk of anaphylaxis with current infusions. Therefore, checking for IgA deficiency ((level <7 mg/dL) or anti-IgA antibodies is recommended before initiating intravenous AAT therapy."}
{"id": "article-31484_40", "title": "Alpha-1 Antitrypsin Deficiency -- Treatment / Management", "content": "While lung transplantation\u00a0has been shown to provide both quality of life and survival benefits for selected patients with severe AAT deficiency, other therapies, such as lung volume reduction therapy, are\u00a0not recommended due to a lack of evidence supporting its use. [29] Management of extrapulmonary manifestations of AAT deficiency requires the following: Regular assessment of liver function is recommended at least annually. [4] In contrast to AAT-related lung disease, augmentation therapy is not recommended for isolated AAT-related liver diseases. Individuals\u00a0with AAT\u00a0deficiency and cirrhosis should undergo screening for hepatocellular carcinoma\u00a0using liver ultrasound\u00a0and serum alpha-fetoprotein. [30] Liver transplantation is the treatment of choice for AAT deficiency associated with advanced liver disease.", "contents": "Alpha-1 Antitrypsin Deficiency -- Treatment / Management. While lung transplantation\u00a0has been shown to provide both quality of life and survival benefits for selected patients with severe AAT deficiency, other therapies, such as lung volume reduction therapy, are\u00a0not recommended due to a lack of evidence supporting its use. [29] Management of extrapulmonary manifestations of AAT deficiency requires the following: Regular assessment of liver function is recommended at least annually. [4] In contrast to AAT-related lung disease, augmentation therapy is not recommended for isolated AAT-related liver diseases. Individuals\u00a0with AAT\u00a0deficiency and cirrhosis should undergo screening for hepatocellular carcinoma\u00a0using liver ultrasound\u00a0and serum alpha-fetoprotein. [30] Liver transplantation is the treatment of choice for AAT deficiency associated with advanced liver disease."}
{"id": "article-31484_41", "title": "Alpha-1 Antitrypsin Deficiency -- Differential Diagnosis", "content": "The differential diagnosis of AAT deficiency lung disease may include the following conditions: Emphysema Chronic bronchitis Bronchiectasis The differential diagnosis of AAT deficiency liver disease may include the following conditions: Chronic viral hepatitis Hereditary hemochromatosis Wilson disease Non-alcoholic steatohepatitis Primary biliary cirrhosis", "contents": "Alpha-1 Antitrypsin Deficiency -- Differential Diagnosis. The differential diagnosis of AAT deficiency lung disease may include the following conditions: Emphysema Chronic bronchitis Bronchiectasis The differential diagnosis of AAT deficiency liver disease may include the following conditions: Chronic viral hepatitis Hereditary hemochromatosis Wilson disease Non-alcoholic steatohepatitis Primary biliary cirrhosis"}
{"id": "article-31484_42", "title": "Alpha-1 Antitrypsin Deficiency -- Prognosis", "content": "During the first three decades of life, liver dysfunction\u00a0poses a\u00a0health threat in individuals with AAT deficiency, while pulmonary dysfunction is less concerning. Beyond the initial decades, the natural history of people with severe AAT deficiency\u00a0becomes less clear, and survival estimates\u00a0can vary among studies due to differences in study populations.", "contents": "Alpha-1 Antitrypsin Deficiency -- Prognosis. During the first three decades of life, liver dysfunction\u00a0poses a\u00a0health threat in individuals with AAT deficiency, while pulmonary dysfunction is less concerning. Beyond the initial decades, the natural history of people with severe AAT deficiency\u00a0becomes less clear, and survival estimates\u00a0can vary among studies due to differences in study populations."}
{"id": "article-31484_43", "title": "Alpha-1 Antitrypsin Deficiency -- Prognosis", "content": "Nonsmoking, asymptomatic individuals with AAT deficiency may have relatively normal survival rates, although confirmation through long-term follow-up in a population-based study is necessary. The FEV1 is a major determinant\u00a0in predicting survival in\u00a0AAT-deficient individuals, with mortality rising as FEV1 falls below 35% of what is predicted. Other parameters used for prognostic evaluation include decreased lung density as assessed by chest CT. [31] [32]", "contents": "Alpha-1 Antitrypsin Deficiency -- Prognosis. Nonsmoking, asymptomatic individuals with AAT deficiency may have relatively normal survival rates, although confirmation through long-term follow-up in a population-based study is necessary. The FEV1 is a major determinant\u00a0in predicting survival in\u00a0AAT-deficient individuals, with mortality rising as FEV1 falls below 35% of what is predicted. Other parameters used for prognostic evaluation include decreased lung density as assessed by chest CT. [31] [32]"}
{"id": "article-31484_44", "title": "Alpha-1 Antitrypsin Deficiency -- Prognosis", "content": "The prognosis for AAT deficiency can vary depending on several factors, including the severity of the disease, the presence of associated complications, and the individual's response to treatment. AAT deficiency-related lung disease can lead to progressive and irreversible lung damage, resulting in COPD, emphysema, and respiratory symptoms.", "contents": "Alpha-1 Antitrypsin Deficiency -- Prognosis. The prognosis for AAT deficiency can vary depending on several factors, including the severity of the disease, the presence of associated complications, and the individual's response to treatment. AAT deficiency-related lung disease can lead to progressive and irreversible lung damage, resulting in COPD, emphysema, and respiratory symptoms."}
{"id": "article-31484_45", "title": "Alpha-1 Antitrypsin Deficiency -- Prognosis", "content": "For individuals with AAT deficiency-related liver disease, the prognosis can also vary. In some cases, liver disease can progress to cirrhosis, which may result in complications such as liver failure or hepatocellular carcinoma. As a result, the prognosis can be grave.", "contents": "Alpha-1 Antitrypsin Deficiency -- Prognosis. For individuals with AAT deficiency-related liver disease, the prognosis can also vary. In some cases, liver disease can progress to cirrhosis, which may result in complications such as liver failure or hepatocellular carcinoma. As a result, the prognosis can be grave."}
{"id": "article-31484_46", "title": "Alpha-1 Antitrypsin Deficiency -- Complications", "content": "Complications of alpha-1 antitrypsin deficiency include: Asthma Emphysema Chronic bronchitis Chronic liver disease", "contents": "Alpha-1 Antitrypsin Deficiency -- Complications. Complications of alpha-1 antitrypsin deficiency include: Asthma Emphysema Chronic bronchitis Chronic liver disease"}
{"id": "article-31484_47", "title": "Alpha-1 Antitrypsin Deficiency -- Deterrence and Patient Education", "content": "Patients with alpha-1 antitrypsin deficiency should be advised to quit smoking, avoid exposure to occupational dust, and have yearly influenza and pneumococcal vaccinations. These measures can help prevent the progression of lung disease and reduce the risk of respiratory infections and associated complications.", "contents": "Alpha-1 Antitrypsin Deficiency -- Deterrence and Patient Education. Patients with alpha-1 antitrypsin deficiency should be advised to quit smoking, avoid exposure to occupational dust, and have yearly influenza and pneumococcal vaccinations. These measures can help prevent the progression of lung disease and reduce the risk of respiratory infections and associated complications."}
{"id": "article-31484_48", "title": "Alpha-1 Antitrypsin Deficiency -- Deterrence and Patient Education", "content": "To prevent secondary complications related to liver disease,\u00a0it is important to advise patients\u00a0to limit alcohol intake or abstain from alcohol altogether. Additionally, hepatitis A and B vaccinations should be recommended.", "contents": "Alpha-1 Antitrypsin Deficiency -- Deterrence and Patient Education. To prevent secondary complications related to liver disease,\u00a0it is important to advise patients\u00a0to limit alcohol intake or abstain from alcohol altogether. Additionally, hepatitis A and B vaccinations should be recommended."}
{"id": "article-31484_49", "title": "Alpha-1 Antitrypsin Deficiency -- Deterrence and Patient Education", "content": "Genetic counseling and testing are recommended for first-degree relatives of\u00a0individuals with AAT\u00a0deficiency due to the increased risk of carrying at-risk alleles associated with AAT deficiency. [13] [33]", "contents": "Alpha-1 Antitrypsin Deficiency -- Deterrence and Patient Education. Genetic counseling and testing are recommended for first-degree relatives of\u00a0individuals with AAT\u00a0deficiency due to the increased risk of carrying at-risk alleles associated with AAT deficiency. [13] [33]"}
{"id": "article-31484_50", "title": "Alpha-1 Antitrypsin Deficiency -- Enhancing Healthcare Team Outcomes", "content": "Optimal management of AAT deficiency requires the collaboration of an interprofessional team of healthcare professionals, including a pediatrician, geneticist, pulmonologist, gastroenterologist, and internist. Regular monitoring of lung function, including FEV1, and periodic chest CT scans are essential for assessing disease progression and guiding treatment decisions. Individualized management plans should be developed based on the patient's specific needs, risk factors, and disease progression to preserve lung function and optimize long-term outcomes", "contents": "Alpha-1 Antitrypsin Deficiency -- Enhancing Healthcare Team Outcomes. Optimal management of AAT deficiency requires the collaboration of an interprofessional team of healthcare professionals, including a pediatrician, geneticist, pulmonologist, gastroenterologist, and internist. Regular monitoring of lung function, including FEV1, and periodic chest CT scans are essential for assessing disease progression and guiding treatment decisions. Individualized management plans should be developed based on the patient's specific needs, risk factors, and disease progression to preserve lung function and optimize long-term outcomes"}
{"id": "article-31484_51", "title": "Alpha-1 Antitrypsin Deficiency -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Alpha-1 Antitrypsin Deficiency -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}